Q-omics provides the consensus-scored GRIN2A profile across patient tissues and cancer cell-line models. GRIN2A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GRIN2A is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, GRIN2A RNA expression shows 15,391 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where GRIN2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIN2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIN2A survival associations across molecular data types. GRIN2A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIN2A RNA expression–survival associations across cancer types. High GRIN2A expression shows unfavorable associations in UVM, THCA and KIRP, but favorable associations in KIRC, HNSC and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GRIN2A RNA expression.
This table summarizes GRIN2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRIN2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIN2A shows lower tumor expression in COAD, BLCA, KICH, UCEC and STAD and higher tumor expression in KIRC. The COAD box plot shows higher GRIN2A RNA expression in normal versus tumor tissue (log2 FC = −0.260, t-test p < 0.001).
This table shows molecular features associated with GRIN2A in patient tissues and cancer cell lines. In patient samples, GRIN2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIN2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
